Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Diabetic Polyneuropathy

Brief Summary: The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.

Detailed Description: SB-509 contains the gene (DNA-a kind of biological "blueprint") for a protein. When a researcher injects SB-509 into your legs, the drug enters the muscle and nerve cells around the injection site and causes these cells to make a protein. This protein causes your cells to increase production of another protein called vascular endothelial growth factor (VEGF), which may improve the structure and function of nerves. In addition, there are changes in the levels of additional proteins in your cells. These proteins function to promote the growth of cells, are structures in cells, help synthesize products, and affect immune cells, and some have unknown functions. This increase in your own VEGF proteins may protect and repair the damaged nerves caused by diabetic neuropathy.

Recruitment & Eligibility

Inclusion Criteria

Clinical diagnosis of Diabetes Mellitus Type I or II for at least 12 months
Clinical signs and symptoms of moderate to severe diabetic sensory-motor polyneuropathy of the lower extremities for at least 6 months that are not otherwise attributed to an etiology other than diabetes
Measurable sural and peroneal response bilaterally
HgbA1C level ≤ 10%
LDL cholesterol ≤ 160 mg/dL
Blood pressure ≤ 140/90 mm Hg
Body mass index (BMI) ≤ 38

Key

Exclusion Criteria

Moderate to severe ischemic heart disease or any history of congestive heart failure, or have had a myocardial infarction within the previous 6 months
Evidence of cardiac enlargement and/or congestive heart failure
Current diabetic foot or leg ulcer, gangrene in the lower extremity, or any amputation of the lower extremity
History of malignancy, except for the following: adequately treated basal cell or squamous cell skin cancer, superficial bladder cancer, adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for at least 5 years
Immune or immunodeficiency disorders or expected to require immunosuppressants for 30 days prior to, during, and for 30 days following administration of the investigational drug product
History of or current proliferative retinopathy, macular edema or retinal neovascularization
Pre-cancerous conditions or benign tumors which have the potential for clinically significant growth due to VEGF stimulation
Family history of inherited neuropathy (e.g. Charcot Marie Tooth, Hereditary Predisposition to Pressure Palsy)

Arm && Interventions

Group	Intervention	Description
SB-509	SB-509	-
Placebo	Saline	Saline

Primary Outcome Measures

Name	Time	Method
To compare the effect of SB-509 versus placebo in subjects with moderately severe diabetic neuropathy (DN) on sural Nerve Conduction Velocity (NCV) at six-months	6 months

Secondary Outcome Measures

Name	Time	Method
To evaluate the effect of SB-509 on Neuropathy Impairment Score - Lower Limb (NIS-LL), motor Nerve Conduction Velocity (NCV), Quantitative Sensory Testing (QST), Intraepidermal Nerve Fiber Density (IENFD), and Lower Extremity Neurological Sensory Exam	12 months
To evaluate the effect of SB-509 using a multi-endpoint analysis that includes NIS-LL, Sural NCV, and IENFD	12 months
To evaluate the safety of SB-509 in subjects with moderately severe diabetic neuropathy	12 months